Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease – a combined tissue microarray, in vitro and in vivo study

BACKGROUND: Targeting signaling pathways is an attractive approach in many malignancies. The PI3K/Akt/mTOR pathway is activated in a number of human neoplasms, accompanied by lower overall and/or disease free survival. mTOR kinase inhibitors have been introduced in the therapy of renal cell carcinom...

Descripción completa

Detalles Bibliográficos
Autores principales: Márk, Ágnes, Hajdu, Melinda, Váradi, Zsófia, Sticz, Tamás Béla, Nagy, Noémi, Csomor, Judit, Berczi, Lajos, Varga, Viktória, Csóka, Monika, Kopper, László, Sebestyén, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665449/
https://www.ncbi.nlm.nih.gov/pubmed/23693095
http://dx.doi.org/10.1186/1471-2407-13-250

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665449/
https://www.ncbi.nlm.nih.gov/pubmed/23693095
http://dx.doi.org/10.1186/1471-2407-13-250

Ejemplares similares